Pharma Business - January 29, 2024
AlzeCure selects drug candidate and enters new phase of development
The company has selected a TrkA-NAM drug candidate, ACD137, and started the preclinical development phase with the compound. “AlzeCure’s unique TrkA-NAM substances have extremely selective effects so that optimal pain-relieving effect is achievable without inducing side effects. As the TrkA-NAM substances are small molecules, they can be taken in tablet form, which makes it easier […]
Agreement - January 24, 2024
Novo Nordisk enters agreement with EraCal Therapeutics
Novo Nordisk has entered into a collaboration and license agreement with the Swiss company EraCal Therapeutics. The two companies will develop and commercialize EraCal’s oral, small molecule program. The asset is believed to target a novel mechanism of action controlling appetite and body weight to treat obesity. Milestones of up to EUR 235 million Novo […]
Agreement - January 23, 2024
Arxx Therapeutics merges with Oxitope Pharma
Norwegian biotech company Arxx Therapeutics will merge with Dutch pharma company Oxitope Pharma to create Calluna Pharma Inc. The merger followed a completed Series A round of EUR 75 million, led by the European investor Forbion, and included existing Arxx investors Sarsia, p53 and Investinor. The funding will last until late 2026, and will support […]
Biotech Business - January 23, 2024
Medivir carries out a directed share issue
The board of directors of Medivir has resolved on a directed issue through which the company receives approximately SEK 20 million before issue costs. The right to subscribe for shares in the Directed Issue shall, with deviation from the shareholders pre-emption rights, belong to Hallberg Management AB (HMAB). HMAB is controlled by Anders Hallberg, former […]
Agreement - January 8, 2024
Novo Nordisk enters into collaborations with Omega Therapeutics and Cellarity
The Omega collaboration will leverage its platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management. The Cellarity collaboration aims to unravel novel biological drivers of MASH and will leverage Cellarity’s platform to develop a small molecule therapy against this disease. […]
Agreement - January 8, 2024
Orion and Glykos enter agreement
Orion Corporation and Glykos Finland have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates (ADCs). Under the agreement, Orion gains access to Glykos’ ADC technologies, initiating an ADC program with the potential for expansion into two additional programs in the future. Orion will be responsible for the target selection, research, […]
